The Increasingly Human and Profitable Monoclonal Antibody Market
The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure o...
Gespeichert in:
| Veröffentlicht in: | Trends in biotechnology (Regular ed.) 2019-01, Vol.37 (1), p.9-16 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 16 |
|---|---|
| container_issue | 1 |
| container_start_page | 9 |
| container_title | Trends in biotechnology (Regular ed.) |
| container_volume | 37 |
| creator | Grilo, António L. Mantalaris, A. |
| description | The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets. |
| doi_str_mv | 10.1016/j.tibtech.2018.05.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2060869618</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167779918301495</els_id><sourcerecordid>2060869618</sourcerecordid><originalsourceid>FETCH-LOGICAL-c595t-dc7589162c012d0b6a0c58b5c5ccbff767bb5c0a018b9099e5e579c15260e3eb3</originalsourceid><addsrcrecordid>eNqFkE1PGzEQhq0KBGngJ7RaiUsvu4w3sb0-UYTaggSCQzhbtne2cdjYqb2LlH-Po6QcuHAajfS88_EQ8o1CRYHyy1U1ODOgXVY10KYCVgGdfyET2ghZzkDyIzLJnCiFkPKUfE1pBQAzIekJOa2lnDNRswn5uVhicedtRJ2c_9tvi9txrX2hfVs8xdC5QZsei4fgg-2D131x7fPi0G6LBx1fcDgjx53uE54f6pQ8__61uLkt7x__3N1c35eWSTaUrRWskZTXFmjdguEaLGsMs8xa03WCC5Mb0PkXI0FKZMiEtJTVHHCGZjYlP_ZzNzH8GzENau2Sxb7XHsOYVA0cGi45bTJ68QFdhTHm2zNFWcOAz-c7iu0pG0NKETu1iW6t41ZRUDvFaqUOitVOsQKmsuKc-36YPpo1tu-p_04zcLUHMOt4dRhVsg69xdZFtINqg_tkxRtrR448</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2158506448</pqid></control><display><type>article</type><title>The Increasingly Human and Profitable Monoclonal Antibody Market</title><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Grilo, António L. ; Mantalaris, A.</creator><creatorcontrib>Grilo, António L. ; Mantalaris, A.</creatorcontrib><description>The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets.</description><identifier>ISSN: 0167-7799</identifier><identifier>EISSN: 1879-3096</identifier><identifier>DOI: 10.1016/j.tibtech.2018.05.014</identifier><identifier>PMID: 29945725</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Asthma ; biosimilars ; Breast cancer ; Colorectal cancer ; Diabetes ; Diabetic retinopathy ; Edema ; Emerging markets ; FDA approval ; Inflammatory bowel disease ; Lung cancer ; Lymphoma ; Manufacturing ; market analysis ; Markets ; Melanoma ; Metastasis ; Monoclonal antibodies ; monoclonal antibody ; Multiple myeloma ; Multiple sclerosis ; Neuroblastoma ; Psoriasis ; Regulatory approval ; Rheumatoid arthritis ; Therapeutic applications</subject><ispartof>Trends in biotechnology (Regular ed.), 2019-01, Vol.37 (1), p.9-16</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jan 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c595t-dc7589162c012d0b6a0c58b5c5ccbff767bb5c0a018b9099e5e579c15260e3eb3</citedby><cites>FETCH-LOGICAL-c595t-dc7589162c012d0b6a0c58b5c5ccbff767bb5c0a018b9099e5e579c15260e3eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2158506448?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29945725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grilo, António L.</creatorcontrib><creatorcontrib>Mantalaris, A.</creatorcontrib><title>The Increasingly Human and Profitable Monoclonal Antibody Market</title><title>Trends in biotechnology (Regular ed.)</title><addtitle>Trends Biotechnol</addtitle><description>The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets.</description><subject>Asthma</subject><subject>biosimilars</subject><subject>Breast cancer</subject><subject>Colorectal cancer</subject><subject>Diabetes</subject><subject>Diabetic retinopathy</subject><subject>Edema</subject><subject>Emerging markets</subject><subject>FDA approval</subject><subject>Inflammatory bowel disease</subject><subject>Lung cancer</subject><subject>Lymphoma</subject><subject>Manufacturing</subject><subject>market analysis</subject><subject>Markets</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>monoclonal antibody</subject><subject>Multiple myeloma</subject><subject>Multiple sclerosis</subject><subject>Neuroblastoma</subject><subject>Psoriasis</subject><subject>Regulatory approval</subject><subject>Rheumatoid arthritis</subject><subject>Therapeutic applications</subject><issn>0167-7799</issn><issn>1879-3096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkE1PGzEQhq0KBGngJ7RaiUsvu4w3sb0-UYTaggSCQzhbtne2cdjYqb2LlH-Po6QcuHAajfS88_EQ8o1CRYHyy1U1ODOgXVY10KYCVgGdfyET2ghZzkDyIzLJnCiFkPKUfE1pBQAzIekJOa2lnDNRswn5uVhicedtRJ2c_9tvi9txrX2hfVs8xdC5QZsei4fgg-2D131x7fPi0G6LBx1fcDgjx53uE54f6pQ8__61uLkt7x__3N1c35eWSTaUrRWskZTXFmjdguEaLGsMs8xa03WCC5Mb0PkXI0FKZMiEtJTVHHCGZjYlP_ZzNzH8GzENau2Sxb7XHsOYVA0cGi45bTJ68QFdhTHm2zNFWcOAz-c7iu0pG0NKETu1iW6t41ZRUDvFaqUOitVOsQKmsuKc-36YPpo1tu-p_04zcLUHMOt4dRhVsg69xdZFtINqg_tkxRtrR448</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Grilo, António L.</creator><creator>Mantalaris, A.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QF</scope><scope>7QO</scope><scope>7QP</scope><scope>7QQ</scope><scope>7QR</scope><scope>7SC</scope><scope>7SE</scope><scope>7SP</scope><scope>7SR</scope><scope>7TA</scope><scope>7TB</scope><scope>7TK</scope><scope>7U5</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8BQ</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F28</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H8D</scope><scope>H8G</scope><scope>HCIFZ</scope><scope>JG9</scope><scope>JQ2</scope><scope>K9.</scope><scope>KR7</scope><scope>L6V</scope><scope>L7M</scope><scope>LK8</scope><scope>L~C</scope><scope>L~D</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201901</creationdate><title>The Increasingly Human and Profitable Monoclonal Antibody Market</title><author>Grilo, António L. ; Mantalaris, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c595t-dc7589162c012d0b6a0c58b5c5ccbff767bb5c0a018b9099e5e579c15260e3eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Asthma</topic><topic>biosimilars</topic><topic>Breast cancer</topic><topic>Colorectal cancer</topic><topic>Diabetes</topic><topic>Diabetic retinopathy</topic><topic>Edema</topic><topic>Emerging markets</topic><topic>FDA approval</topic><topic>Inflammatory bowel disease</topic><topic>Lung cancer</topic><topic>Lymphoma</topic><topic>Manufacturing</topic><topic>market analysis</topic><topic>Markets</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>monoclonal antibody</topic><topic>Multiple myeloma</topic><topic>Multiple sclerosis</topic><topic>Neuroblastoma</topic><topic>Psoriasis</topic><topic>Regulatory approval</topic><topic>Rheumatoid arthritis</topic><topic>Therapeutic applications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grilo, António L.</creatorcontrib><creatorcontrib>Mantalaris, A.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Aluminium Industry Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Electronics & Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Materials Business File</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>SciTech Premium Collection</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Civil Engineering Abstracts</collection><collection>ProQuest Engineering Collection</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>ProQuest Biological Science Collection</collection><collection>Computer and Information Systems Abstracts Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in biotechnology (Regular ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grilo, António L.</au><au>Mantalaris, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Increasingly Human and Profitable Monoclonal Antibody Market</atitle><jtitle>Trends in biotechnology (Regular ed.)</jtitle><addtitle>Trends Biotechnol</addtitle><date>2019-01</date><risdate>2019</risdate><volume>37</volume><issue>1</issue><spage>9</spage><epage>16</epage><pages>9-16</pages><issn>0167-7799</issn><eissn>1879-3096</eissn><abstract>The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>29945725</pmid><doi>10.1016/j.tibtech.2018.05.014</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-7799 |
| ispartof | Trends in biotechnology (Regular ed.), 2019-01, Vol.37 (1), p.9-16 |
| issn | 0167-7799 1879-3096 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2060869618 |
| source | Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Asthma biosimilars Breast cancer Colorectal cancer Diabetes Diabetic retinopathy Edema Emerging markets FDA approval Inflammatory bowel disease Lung cancer Lymphoma Manufacturing market analysis Markets Melanoma Metastasis Monoclonal antibodies monoclonal antibody Multiple myeloma Multiple sclerosis Neuroblastoma Psoriasis Regulatory approval Rheumatoid arthritis Therapeutic applications |
| title | The Increasingly Human and Profitable Monoclonal Antibody Market |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A14%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Increasingly%20Human%20and%20Profitable%20Monoclonal%20Antibody%20Market&rft.jtitle=Trends%20in%20biotechnology%20(Regular%20ed.)&rft.au=Grilo,%20Ant%C3%B3nio%20L.&rft.date=2019-01&rft.volume=37&rft.issue=1&rft.spage=9&rft.epage=16&rft.pages=9-16&rft.issn=0167-7799&rft.eissn=1879-3096&rft_id=info:doi/10.1016/j.tibtech.2018.05.014&rft_dat=%3Cproquest_cross%3E2060869618%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2158506448&rft_id=info:pmid/29945725&rft_els_id=S0167779918301495&rfr_iscdi=true |